# Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

> **NCT05407441** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Susan Chi, MD** · enrollment: 49 (estimated)

## Conditions studied

- Atypical Teratoid Rhabdoid Tumor
- INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors
- SMARCA4-deficient Primary CNS Malignant Tumors
- Malignant Rhabdoid Tumor (MRT)
- Rhabdoid Tumor of the Kidney (RTK)
- Epithelioid Sarcoma
- Chordoma

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT05407441
- **Lead sponsor:** Susan Chi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2027-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407441, "Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05407441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*